TrialAdvance, Inc. Establishes New Strategy Group Focused on Underrepresented Populations in Clinical Trials: Rebecca Budd to Head Group

CHICAGO — Kathleen B. Drennan, president and CEO of TrialAdvance , Inc., announces the creation of a new strategy group called iDICT (Improving Disparities In Clinical Trials). The iDICT Group will help study sponsors achieve the federal government’s directive to increase participation of underrepresented populations in clinical trials. Rebecca Budd will serve as the group’s managing director and chief strategist. “Despite the fact that the government issued its strongest recommendations yet about the need to address participation of minorities,